Table 2a.
Combined Patient Outcomes
| Home HCT (N=25) | Matched Controls (N=50) | P-value1 | |
|---|---|---|---|
| Mean Number of Clinic Visits (IQR) | 8.1 (3–10) | 23.5 (13.3–30.5) | <0.001 |
| Mean Days Hospitalized (IQR) | 8.9 (1–10) | 11.3 (0–17) | 0.44 |
| Mean Percent Time Hospitalized (IQR) | 21% (4%–32%) | 27% (0%–40%) | 0.36 |
| Median Days to Engraftment (IQR) | 13 (12–16) | 12 (11–17) | 0.92 |
| Incidence of Febrile Neutropenia | 16 (64%) | 38 (76%) | 0.28 |
| Median Days of Febrile Neutropenia (IQR) | 7.5 (4.75–9.25) | 5 (3.25–10.75) | 0.91 |
| Clinically-Significant BSI2 Peri-Transplant | 7 (28%) | 8 (16%) | 0.22 |
| LCBI3 Peri-Transplant | 6 (24%) | 5 (10%) | 0.16 |
| MBI-LCBI4 Peri-Transplant | 2 (8%) | 4 (8%) | 0.99 |
| Respiratory Infection Peri-Transplant | 3 (12%) | 5 (10%) | 0.99 |
| C. difficile Infection Peri-Transplant | 0 (0%) | 4 (8%) | 0.29 |
| Clinically-Significant BSI2 1 Year Post-Transplant | 8 (32%) | 9 (18%) | 0.17 |
| LCBI3 1 Year Post-Transplant | 7 (28%) | 5 (10%) | 0.09 |
| MBI-LCBI4 1 Year Post-Transplant | 2 (8%) | 4 (8%) | 0.99 |
| Respiratory Infection 1Year Post-Transplant | 5 (20%) | 6 (12%) | 0.49 |
| C. difficile Infection 1 Year Post-Transplant | 0 (0%) | 6 (12%) | 0.17 |
1
P-values obtained via t-test, Fisher’s exact test, or Chi-square test.
2
BSI: Bloodstream Infection.
3
LCBI: Laboratory-Confirmed Bloodstream Infection.
4
MBI-LCBI: Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infection.